{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024215","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.304417+00:00","generated_at":"2026-06-21T23:36:04.365469+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tango Therapeutics Q3 2022 net loss $29.1M; cash $393.3M; pipeline advances","bullets":["Net loss $29.1M ($0.33/share) vs $19.6M ($0.28) year ago; cash $393.3M sufficient into 2025.","TNG908 phase 1/2 trial enrolling; CTA approved in France; initial safety and efficacy data expected H1 2023.","Disclosed TNG260 as CoREST inhibitor for STK11-mutant cancers; IND filing on track for H1 2023.","Declared TNG348 development candidate for BRCA1/2-mutant cancers; IND filing planned for 2023.","Appointed Aaron Weitzman as CMO; R&D expenses $28.7M, G&A $8.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024215","json":"https://secwatch.observer/filing/0000950170-22-024215.json","markdown":"https://secwatch.observer/filing/0000950170-22-024215.md","text":"https://secwatch.observer/filing/0000950170-22-024215.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017022024215/0000950170-22-024215-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017022024215/tngx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:36:04.365469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88f3462d5503dde150e1374a85c9dd440535166e","claim":"Tango Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $6.9 million.","evidence_excerpt":"held $393.3 million in cash, cash equivalents and marketable securities, which the Company believes to be sufficient to fund operations into 2025. Collaboration revenue was $6.9 million for the three months ended September 30, 2022, compared to $6.8 million for the same period in 2021, and $18.4 million for the nine months ended September 30, 2022 compared to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017022024215/0000950170-22-024215-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$6.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}